Myoform Launches Genetically Personalized Supplements to Redefine Athletic Performance

Myoform, the precision nutrition startup applying the science of genomics to consumer health, today announced the official launch of its genetically personalized supplement platform to its 500+ strong waitlist of athletes and active consumers.

The patent-pending Myoform system combines whole-genome sequencing, biometric profiling, and AI-driven analysis to deliver bespoke supplement formulations and health insights. Each monthly supply is uniquely tailored to the individual, addressing nutrient deficiencies, optimizing recovery, and reducing injury risk through truly personalized dosing.

During beta-testing, participants reported up to a 23.5% improvement in performance across seven domains within three months, including strength endurance, aerobic capacity, and recovery speed.

“The supplement aisle is crowded with generic products making questionable claims and underdosed ingredients,” said Theo Wiley, CEO and Founder of Myoform. “We’re cutting through the noise by applying the same principles of precision medicine used in biotech to sports and performance. For the first time, consumers don’t just get data. They get direct, science-backed interventions they can feel, optimized for their biology”

Myoform’s launch positions it as the first mover in genetically personalized supplements for performance, targeting athletes, sports teams, and health-conscious consumers who are tired of guesswork in nutrition.

Key features include:

• A one-time at-home DNA test or integration with existing genetic data
• Proprietary algorithm generating N-of-1 powdered supplements, produced in-house with NSF/Informed Sport certified ingredients
• A companion app delivering detailed health and training insights (nutrient risks, training response, injury predisposition)
• Optional blood biomarker testing add-on coming soon for even deeper personalization
• Ongoing updates as new research, biomarkers, and wearable data are integrated

The launch begins with a controlled rollout to Myoform’s waitlist before broader expansion in the UK and US later this year.